人工膵臓デバイスシステムの世界市場2016-2020

◆英語タイトル:Global Artificial Pancreas Devices System Market 2016-2020
◆商品コード:IRTNTR11134
◆発行会社(調査会社):Technavio
◆発行日:2016年12月14日
◆ページ数:85
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、人工膵臓デバイスシステムの世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、人工膵臓デバイスシステムの世界市場規模及び予測、市場シェア、カテゴリ別分析、地域別分析/市場規模、市場の成長要因、市場の課題、医療費償還シナリオ、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Artificial Pancreas Devices System
Artificial organs are human-made bioartificial devices, which are implanted or integrated into individuals to replace or support natural organs. These include artificial heart, kidney, pancreas, and cochlear implants. Biocompatible materials such as polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ceramics, and metals are used to develop artificial organs. These organs are incorporated with different technologies like sensors, biomaterials, and innovative delivery systems. Artificial organs perform the function of the natural organ and help the patient to live a quality life. In few cases, artificial organs are capable of eliminating the need for organ transplantation altogether.

Technavio’s analysts forecast the global artificial pancreas devices system market to grow at a CAGR of 7.40% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global artificial pancreas devices system market for 2016-2020. To calculate the market size, the report considers the revenue generated from sales of the different products.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Artificial Pancreas Devices System Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Medtronic
• Johnson & Johnson
• Insulet
• Tandem Diabetes Care
• Roche

[Other prominent vendors]
• Beta Bionics
• Bigfoot Biomedical
• Cellnovo
• Dexcom
• Dose Safety
• DreaMed Diabetes
• Inreda Diabetic
• Type Zero Technologies

[Market driver]
• Growing technological integration fueling the market growth.
• For a full, detailed list, view our report

[Market challenge]
• Lack of smart control algorithms affecting the adoption rate of existing APDS.
• For a full, detailed list, view our report

[Market trend]
• Growing demand for remote monitoring application.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• A glance at parent market: Artificial organs

PART 05: An overview of pancreas and diabetes
• Pancreas
• Diabetes
• Insulin overview

PART 06: Need for better systems in the management of diabetes

PART 07: Artificial pancreas device system
• Technology landscape

PART 08: Initiatives for the development of APDS
• Juvenile Diabetes Research Foundation (JDRF) initiative — 2006
• European Commission’s AP@home project — 2010
• Centre for bio-inspired technology — Bionic pancreas
• Harvard University — 2014

PART 09: FDA’s role in fostering the development of APDS
• Rapid response to preliminary study plans
• Interactive review of investigational device exemption study plans
• Guidance and standards for researchers and industry

PART 10: Reimbursement scenario
• Australia
• Germany
• UK
• US

PART 11: Key clinical trials

PART 12: Market landscape
• Market overview
• Five forces analysis

PART 13: Market segmentation by categories
• TSDS
• NTSDS
• CTRS
• CTTS

PART 14: Geographical segmentation
• APDS market in Americas
• APDS market in EMEA
• APDS market in APAC

PART 15: Market drivers
• Growing technological integration fuelling the market growth
• Increasing initiatives of research organizations fostering innovation in the market
• Increasing prevalence of diabetes fuelling the need for effective devices

PART 16: Impact of drivers

PART 17: Market challenges
• Lack of smart control algorithms affecting the adoption rate of existing APDS
• Low penetration rates affecting the market growth
• Lab-grown pancreatic cell transplant as a potential treatment alternative hindering the growth prospects

PART 18: Impact of drivers and challenges

PART 19: Market trends
• Increasing focus on closed loop systems
• Growing demand for remote monitoring applications
• Focus of new entrants on the development of novel APDS

PART 20: Vendor landscape
• Competitive scenario

PART 21: Key vendor analysis
• Medtronic
• Johnson & Johnson
• Insulet
• Tandem Diabetes Care
• Roche
• Other prominent vendors

PART 22: Appendix
• List of abbreviations

PART 23: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key segments in artificial organ market
Exhibit 03: Diagnosis of diabetes by blood sugar test
Exhibit 04: Diagnosis of diabetes by glycated hemoglobin test
Exhibit 05: Treatment algorithm for type 2 diabetes
Exhibit 06: Factors that fuelled the need for APDS
Exhibit 07: Technology involved in the functioning of APDS
Exhibit 08: Barriers in CGM
Exhibit 09: Barriers in hormonal pumps
Exhibit 10: Key findings of researchers related to algorithms till date
Exhibit 11: Key clinical trials
Exhibit 12: Global APDS market snapshot
Exhibit 13: Development path of APDS
Exhibit 14: Global APDS market 2015-2020 ($ millions)
Exhibit 15: Key factors driving the demand for closed loop systems
Exhibit 16: Scenario analysis of global APDS market
Exhibit 17: Five forces analysis
Exhibit 18: Pipeline products
Exhibit 19: Key pipeline products
Exhibit 20: Scenario analysis of key segments in global APDS market
Exhibit 21: Segmentation of global APDS market based on geography 2015 and 2020
Exhibit 22: APDS market revenue by geography 2015-2020 ($ millions)
Exhibit 23: Market scenario in Americas
Exhibit 24: APDS market in the Americas ($ millions)
Exhibit 25: Market scenario in EMEA
Exhibit 26: APDS market in EMEA ($ millions)
Exhibit 27: Market scenario in EMEA
Exhibit 28: APDS market in APAC ($ millions)
Exhibit 29: Key technological integrations
Exhibit 30: Key initiatives of research organizations
Exhibit 31: Incidence and prevalence for diabetes in the US
Exhibit 32: Traditional systems vs APDS
Exhibit 33: Impact of drivers
Exhibit 34: Forcefield analysis of drivers and challenges
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Key trends in the development of closed loop systems
Exhibit 37: Key products under development for remote monitoring applications
Exhibit 38: New entrants and their expected product launches
Exhibit 39: Competitive structure analysis of global APDS market 2015
Exhibit 40: Competitive analysis of global APDS market
Exhibit 41: Market share analysis 2015
Exhibit 42: Market penetration of various APDS manufacturers in global (2015)
Exhibit 43: Timeline chart representing the development of APDS
Exhibit 44: Strategic success factors of companies in global APDS market
Exhibit 45: Key highlights
Exhibit 46: Strength assessment
Exhibit 47: Strategy assessment
Exhibit 48: Opportunity assessment
Exhibit 49: Key highlights
Exhibit 50: Strength assessment
Exhibit 51: Strategy assessment
Exhibit 52: Opportunity assessment
Exhibit 53: Key highlights
Exhibit 54: Strength assessment
Exhibit 55: Strategy assessment
Exhibit 56: Opportunity assessment
Exhibit 57: Key highlights
Exhibit 58: Strength assessment
Exhibit 59: Strategy assessment
Exhibit 60: Opportunity assessment
Exhibit 61: Key highlights
Exhibit 62: Strength assessment
Exhibit 63: Strategy assessment
Exhibit 64: Opportunity assessment



【掲載企業】

Medtronic, Johnson & Johnson, Insulet, Tandem Diabetes Care, Roche, Beta Bionics, Bigfoot Biomedical, Cellnovo, Dexcom, Dose Safety, DreaMed Diabetes, Inreda Diabetic, Type Zero Technologies.

【レポートのキーワード】

人工膵臓、人工臓器

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[人工膵臓デバイスシステムの世界市場2016-2020]販売に関する免責事項
★調査レポート[人工膵臓デバイスシステムの世界市場2016-2020]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆